Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Ltd.
Your view on VFY.AX
Overview
What the company does, where it operates, and who runs it.
About Vitrafy Life Sciences Ltd.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Brenton Michael Leslie Owens
- Headquarters
- Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC, AU
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Brenton Michael Leslie Owens
- Headquarters
- Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC, AU
Vitrafy Life Sciences Limited has developed cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets, cell & gene therapies, aquaculture and bovine reproduction.
The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain software platform, and Smart Packaging systems.
Vitrafy has designed and developed an innovative cryopreservation solution, which includes smart cryopreservation medical devices and packaging, and a sample quality management software platform known as LifeChain.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vitrafy Life Sciences Ltd., and the rating behind it. VFY.AX last traded at AUD 3.99; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vitrafy Life Sciences Ltd.. Starting points for Vitrafy Life Sciences Ltd.: EPS -AUD 0.22, beta 1.93 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vitrafy Life Sciences Ltd.. Vitrafy Life Sciences Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vitrafy Life Sciences Ltd.. Trailing twelve-month EPS for Vitrafy Life Sciences Ltd. stands at -AUD 0.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vitrafy Life Sciences Ltd.. Vitrafy Life Sciences Ltd. has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vitrafy Life Sciences Ltd. valued side by side against its closest peers. Vitrafy Life Sciences Ltd. is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vitrafy Life Sciences Ltd., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vitrafy Life Sciences Ltd. executives and directors. Shares of Vitrafy Life Sciences Ltd. have traded between AUD 1.16 and AUD 4.09 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vitrafy Life Sciences Ltd.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vitrafy Life Sciences Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vitrafy Life Sciences Ltd.. Coverage tracks Vitrafy Life Sciences Ltd. within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.